Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Atnahs Pharma Netherlands B.V., Strawinskylaan 3127, 1077 ZX Amsterdam, Netherlands
Bondronat 6 mg concentrate for solution for infusion.
Pharmaceutical Form |
---|
Concentrate for solution for infusion. |
One vial with 6 ml concentrate for solution for infusion contains 6 mg ibandronic acid (as sodium monohydrate).
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Ibandronic acid |
Ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone. Their selective action on bone tissue is based on the high affinity of bisphosphonates for bone mineral. Bisphosphonates act by inhibiting osteoclast activity, although the precise mechanism is still not clear. In vivo, ibandronic acid prevents experimentally-induced bone destruction caused by cessation of gonadal function, retinoids, tumours or tumour extracts. |
List of Excipients |
---|
Sodium chloride |
Bondronat is supplied as packs containing 1, 5 and 10 vials (6 ml type I glass vial with a bromobutyl rubber stopper). Not all pack sizes may be marketed.
Atnahs Pharma Netherlands B.V., Strawinskylaan 3127, 1077 ZX Amsterdam, Netherlands
EU/1/96/012/011
EU/1/96/012/012
EU/1/96/012/013
Date of first authorisation: 25 June 1996
Date of latest renewal: 25 June 2006
Drug | Countries | |
---|---|---|
BONDRONAT | Austria, Australia, Germany, Ecuador, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Lithuania, Netherlands, Poland, Singapore, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.